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Eosinophilic angiocentric ﬁbrosis (EAF) is an exceeding rare clinical entity and is considered a part of the spectrum of IgG4related disease (IgG4RD). We hereby present such an unusual case of a 60-year-old female who presented to us with recurrent
sinonasal mass, after a decade long haul of multiple clinical evaluations, biopsies, and debulking surgery without a deﬁnitive
diagnosis. Over this period, the mass eroded through the ethmoid cells along with nasal septal destruction leading to saddle nose
deformity, extended superiorly through the cribriform plates to right frontal lobe, and compressed the optic nerve leading to visual
loss. Although initial biopsy was negative, repeat biopsy was performed owing to high clinical suspicion due to all the classic
histopathological ﬁndings compatible with the diagnosis of eosinophilic angiocentric ﬁbrosis IgG4-related disease (EAFIgG4RD). Steroids are the recommended ﬁrst-line therapy; however, our case was resistant to steroids needing rituximab to halt
the disease progression. Our case interestingly also had T-cell clonality and isolated isocitrate dehydrogenase 2 enzyme mutation
on next-generation sequencing, suggesting a possible role of novel molecular-targeted therapies in this rare disease. This case
highlights the clinical challenges physicians face towards diagnosing and treating EAF-IgG4RD, emphasizing the need for high
clinical suspicion and the possible role of targeted therapies for this rare disease.

1. Introduction
Immunoglobulin G4-related disease (IgG4RD) is a recently
recognized systemic disease characterized by immunemediated ﬁbroinﬂammation. Although the early descriptions
date back to the 1960s, IgG4RD as a uniﬁed entity with
systemic manifestations was recognized only in 2001 [1, 2].
Eosinophilic angiocentric ﬁbrosis (EAF) is a rare localized
tumefactive disease involving upper respiratory tract and
orbit, considered to be a part of spectrum of systemic IgG4RD
[3]. We hereby present a case of steroid-resistant eosinophilic
angiocentric ﬁbrosis IgG4-related disease (EAF-IgG4RD)
presenting as an invasive mass-like lesion of ethmoid sinus

with T-cell clonality and isocitrate dehydrogenase 2 enzyme
(IDH-2) mutation, highlighting the diﬃculties clinicians face
in diagnosing and treating this rare disease.

2. Case Presentation
In 2010, a 60-year-old female presented with a right-sided nasopharyngeal mass and imaging revealed soft tissue mass along
the inferior nasal cavity with intact ethmoid roof and cribriform
plate. Biopsy was nondiagnostic at that time and showed foamy
histocytes with acute on chronic inﬂammatory changes.
Over the following decade, she consulted multiple
healthcare providers across the nation as she continued to
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Figure 1: Triplanar MRI coronal STIR (a), axial STIR (b), and sagittal (c) T1-ﬂair with fat saturation postcontrast showing midline anterior
skull base mass with extension through skull base and right lamina papyracea (arrows) and saddle nose deformity (star).

experience recurrent symptoms of nasal obstruction, epistaxis, hyposmia, nasalization of speech, and sinusitis.
Computed tomography (CT) scans revealed progressive
local changes with erosion through the ethmoid cells and
nasal septal destruction causing saddle nose deformity. She
in total underwent 7 biopsies, all reported as nonspeciﬁc
mixed inﬂammatory changes with lymphocytic proliferation. Her mass continued to recur, requiring repeated
debulking leading to considerable morbidity including
eustachian tube dysfunction and right-sided hearing loss.
She presented to our hospital in late 2019 with complete
right eye vision loss and worsening vision in the left eye.
Magnetic resonance imaging (MRI) revealed a 4.2 cm mass
in the right ethmoid and inferior frontal sinus traversing
cribriform plates, compressing bilateral optic nerves, and
extending to the right inferior frontal lobe (Figure 1). Serum
eosinophil counts were normal at 0.14 k/μL. Serum IgA and
IgM were also reported normal 178 mg/dL and 146 mg/dL,

respectively. IgG levels were low at 497 mg/dL with normal
serum IgG4 levels at 53.9 mg/dL. Repeat biopsy showed
mixed acute and chronic inﬂammatory process with foamy
macrophages and background sclerosis. Immunohistochemistry revealed a mixed T-cell and B-cell populations
and <10 IgG4-positive plasma cells per high power ﬁeld
(HPF). Serum IgG4 level and peripheral blood ﬂow
cytometry were normal. FDG-PET scan showed ethmoid
sinus soft tissue mass extending into the right inferior frontal
lobe with a SUV of 8.8 and a nodular soft tissue thickening
along the left inferior nasal cavity eroding into hard palate
with a SUV of 7.5. Due to rapidly deteriorating vision from
extrinsic optic nerve compression and edema, she received
high-dose IV methylprednisolone 1000 mg for 3 days followed by prednisone 60 mg daily tapered over 8 weeks.
Despite transient improvement, her visual loss continued to
worsen. In further case discussion, atypical non-Langerhans
histiocytosis was considered as a diﬀerential diagnosis by
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Figure 2: (a) Obliterative phlebitis—20x hematoxylin and eosin (H&E) stain showing cellular ﬁbroinﬂammatory zone with irregular elastic
remnants of larger vein; (b) storiform ﬁbrosis—20x H&E stain showing paucicellular zone of whorled and interlacing collagen bundles with
residual spindle-shaped ﬁbroblast nuclei; (c) lymphoplasmacytic inﬁltration—40x H&E stain showing densely cellular inﬂammatory
inﬁltrate with numerous plasma cells and eosinophils in a ﬁbrous matrix; (d) immunohistochemistry shows strong positive brown
chromogen decoration of IgG4-positive lymphoid cells, exceeding 50/high power ﬁeld.

pathologists, and she received local radiation to sinonasal
mass with 4500 cGy, yet her symptoms did not improve. Of
note, next-generation sequencing (NGS) was positive for
isolated IDH-2 enzyme mutation and T-cell receptor
analysis showed clonality. Repeat FDG-PET postradiation
showed no signiﬁcant change in the size and uptake of the
mass. Given unclear etiology and minimal response to
steroids and radiation, a repeat biopsy of the mass was
pursued. This revealed eosinophilic inﬁltrates admixed with
lymphoplasmacytic inﬂammatory cells with angiocentric
ﬁbrosis, vascular obliteration, and immunohistochemical
stains were positive for IgG4 at > 50 cells/HPF, compatible
with the diagnosis of IgG4RD (Figure 2). Her disease was
deemed steroid refractory, and rituximab was initiated at
1000 mg IV every 15 days for a total of 2 doses. Both her
visual symptoms and nasal obstruction began to improve,
and sinonasal mass decreased to 2.3 cm on repeat MRI scan.

3. Discussion
IgG4RD is immune-mediated systemic ﬁbroinﬂammatory
disease aﬀecting multiple organs, leading to tumefactive
tissue destruction [1–4]. EAF is a rare form localized
sinonasal IgG4RD, commonly sinonasal cavity and orbits
[3]. EAF-IgG4RD has a predilection for local extension
associated with osseous destruction and perineural

inﬁltration [3, 5–8]. High clinical suspicion is needed as
these are frequently misdiagnosed as inﬂammatory or
cancerous lesions given extensive local invasion and hypermetabolic appearance on FDG-PET scans, delaying appropriate treatment and resulting in unwarranted
complications [9, 10].
The three major hallmark histopathological ﬁndings of
IgG4RD are dense lymphoplasmacytic inﬁltrate, storiform
ﬁbrosis, and obliterative phlebitis. Diagnosis also requires
the presence of increased IgG4-positive plasma cells or elevated IgG4 : IgG ratio in the tissue [1]. Although the
number of IgG4-positive plasma cells varies based on the
organ involved and degree of ﬁbrosis, diﬀuse inﬁltration
with >50 cells/HPF is considered highly speciﬁc for IgG4RD
[1, 11]. Proposed to be a form of IgG4RD, histologically
EAF-IgG4RD is identiﬁed by the distinctive presence of
small caliber angiocentric ﬁbrosis and eosinophil-dominant
inﬂammatory inﬁltrates [3]. Prior biopsies in our case were
either reported as nonspeciﬁc lacking the hallmark histopathological ﬁndings or having <10 IgG4 cells/HPF, not
meeting the diagnostic criteria for IgG4RD. At times,
sampling noninvolved portion or portion with predominant
ﬁbrosis may lead to false-negative results. Also, given the
complexity of the diagnosis, histopathological examination
should ideally be performed by an experienced pathologist
to avoid inconclusive results. As such, if the clinical
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suspicion is high with no other alternative diagnosis, repeat
biopsy should be considered. Final biopsy performed at our
institution showed >50 IgG4 cells/HPF along with other
required histopathological ﬁndings, establishing the diagnosis of EAF-IgG4RD.
T-cells play a signiﬁcant role in the pathophysiology of
IgG4RD including the oligoclonal expansion of
CD4 + SLAMF7 + cytotoxic T-lymphocytes (CTLS) and
T-follicular helper cells, compatible with the observed T-cell
clonality in our patient’s tissue biopsy in the absence of
morphologic evidence of T-cell lymphoma [12–15]. Of note,
heretofore, there is no report on IDH-2 mutation in
IgG4RD, which was puzzling for us and, for a moment,
raised the concern for a small angioimmunoblastic T-cell
lymphoma clone driving plasma cell activation, yet no
further supportive evidence was found [16]. The exact
meaning of the observed IDH-2 mutation is not clear, yet
our case suggests that IDH-2 mutations may be present in
IgG4RD and that NGS proﬁling may help to better understand disease biology and to identify novel molecular
therapeutic targets in this rare disease.
Prednisone 0.6 mg/kg/day for a total of 4 weeks followed
by taper and discontinuation in 2-3 months is the recommended treatment for IgG4RD [17]. This is largely based on
expert opinions and from clinical experiences in treating
autoimmune pancreatitis. Rituximab was shown to be a
promising alternative agent with an overall response rate of
83% even among cases resistant to steroids and immunomodulators [18–22]. Currently recommended dose regimen
is 1000 mg IV every 15 days for a total of 2 doses. Given
aggressive local destruction, intracranial invasion with vision loss, and recrudescence with initial steroid therapy, we
opted for rituximab as a steroid alternative treatment option
in our case and achieved desired clinical response. Use of
rituximab in combination with ﬂudarabine or bendamustine
was also reported especially among cases of IgG4RD
coexisting hyperviscosity syndrome [3, 23–25]. Use of rituximab alone achieved desired clinical response in our case
without the need for alternative regimens.
EAF-IgG4RD can be challenging to diagnose, and a high
index of clinical suspicion followed by focused clinicopathological examination is the key for establishing the
correct diagnosis. Our case reﬂects a 10-year journey similar
to Odysseus’ return to Ithaca after the Trojan War. Whether
in addition to current imaging and histopathology, the
detection of molecular targets such as the observed IDH-2
mutation will be helpful in diagnosis, and management of
IgG4RD warrants to be explored further, as subtle coincidental ﬁndings often mean a lot, similar to Eurycleia recognizing Odysseus by his scar above the knee (Odyssey
19.386-507).
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